First Brands Group debt targeted by Apollo Global Management - report
MOUNTAIN VIEW, Calif. - Iridex Corporation (NASDAQ:IRIX), a provider of laser-based medical systems for eye treatments with a market capitalization of $22.94 million and annual revenue of $49.74 million, announced Tuesday it has regained compliance with Nasdaq’s continued listing requirements.
The company had received a non-compliance notification on May 14, 2025, based on its quarterly report for the period ended March 29, 2025, which indicated it did not meet the standards set in Nasdaq Listing Rule 5550(b).
According to the formal notification received from Nasdaq on August 27, 2025, Iridex has successfully satisfied the minimum stockholders’ equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market. This compliance was confirmed based on the company’s quarterly report for the period ended June 28, 2025, which was filed on August 12, 2025.
Nasdaq has now closed the matter, allowing Iridex to maintain its listing on the exchange without further action required.
Iridex develops and manufactures laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology applications. The company’s products, which include its proprietary MicroPulse technology, are used primarily for treating glaucoma, diabetic macular edema, and other retinal diseases.
The company markets its products directly in the United States and through distributors internationally in over 100 countries, according to the press release statement.
In other recent news, IRIDEX Corporation reported its second-quarter earnings for 2025, surpassing expectations. The company achieved an earnings per share (EPS) of -$0.06, which was better than the projected -$0.09. Additionally, IRIDEX exceeded revenue forecasts by reporting $13.6 million, compared to the anticipated $13.1 million. These developments indicate a stronger-than-expected financial performance for the quarter. The earnings announcement has garnered attention from investors and analysts alike. While specific analyst upgrades or downgrades were not mentioned, the results may influence future evaluations. The recent performance highlights IRIDEX’s ability to surpass financial expectations in a competitive market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.